AVID BIOSERVICES INC (CDMO) Stock Fundamental Analysis

NASDAQ:CDMO • US05368M1062

12.49 USD
+0.01 (+0.08%)
Last: Feb 4, 2025, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CDMO. CDMO was compared to 521 industry peers in the Biotechnology industry. CDMO may be in some trouble as it scores bad on both profitability and health. CDMO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year CDMO has reported negative net income.
  • In the past year CDMO had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: CDMO reported negative net income in multiple years.
  • CDMO had a positive operating cash flow in 4 of the past 5 years.
CDMO Yearly Net Income VS EBIT VS OCF VS FCFCDMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • The Return On Assets of CDMO (-47.00%) is comparable to the rest of the industry.
  • The Return On Equity of CDMO (-339.34%) is worse than 76.46% of its industry peers.
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROIC N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
CDMO Yearly ROA, ROE, ROICCDMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

  • CDMO has a Gross Margin of 7.68%. This is in the better half of the industry: CDMO outperforms 73.81% of its industry peers.
  • In the last couple of years the Gross Margin of CDMO has declined.
  • CDMO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
CDMO Yearly Profit, Operating, Gross MarginsCDMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CDMO has more shares outstanding
  • CDMO has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CDMO has a worse debt to assets ratio.
CDMO Yearly Shares OutstandingCDMO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDMO Yearly Total Debt VS Total AssetsCDMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -0.51, we must say that CDMO is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of -0.51, CDMO is doing good in the industry, outperforming 61.95% of the companies in the same industry.
  • CDMO has a Debt/Equity ratio of 3.58. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of CDMO (3.58) is worse than 84.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Altman-Z -0.51
ROIC/WACCN/A
WACC8.72%
CDMO Yearly LT Debt VS Equity VS FCFCDMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • CDMO has a Current Ratio of 1.30. This is a normal value and indicates that CDMO is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CDMO (1.30) is worse than 83.89% of its industry peers.
  • CDMO has a Quick Ratio of 1.30. This is a bad value and indicates that CDMO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CDMO has a worse Quick ratio (0.92) than 87.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
CDMO Yearly Current Assets VS Current LiabilitesCDMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • CDMO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1305.88%.
  • CDMO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.80%.
  • CDMO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.15% yearly.
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%

3.2 Future

  • Based on estimates for the next years, CDMO will show a very strong growth in Earnings Per Share. The EPS will grow by 27.71% on average per year.
  • CDMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.14% yearly.
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CDMO Yearly Revenue VS EstimatesCDMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CDMO Yearly EPS VS EstimatesCDMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CDMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDMO Price Earnings VS Forward Price EarningsCDMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDMO Per share dataCDMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CDMO's earnings are expected to grow with 27.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y27.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CDMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AVID BIOSERVICES INC

NASDAQ:CDMO (2/4/2025, 8:00:02 PM)

12.49

+0.01 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-10
Earnings (Next)04-22
Inst Owners105.25%
Inst Owner Change0%
Ins Owners0.95%
Ins Owner Change0%
Market Cap801.11M
Revenue(TTM)150.44M
Net Income(TTM)-152.05M
Analysts74.55
Price Target12.75 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-92.85%
Min EPS beat(2)-125.28%
Max EPS beat(2)-60.43%
EPS beat(4)0
Avg EPS beat(4)-1306.42%
Min EPS beat(4)-4971.9%
Max EPS beat(4)-60.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-3.38%
Max Revenue beat(2)-2.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.38%
Max Revenue beat(4)-0.02%
Revenue beat(8)3
Avg Revenue beat(8)-3.35%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)11
Avg Revenue beat(16)3.84%
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-1.69%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.32
P/FCF N/A
P/OCF 152.36
P/B 17.88
P/tB 17.88
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.08
OCFY0.66%
SpS2.35
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.68%
FCFM N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 119.78%
Cap/Sales 9.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z -0.51
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)874.1%
Cap/Depr(5y)606.28%
Cap/Sales(3y)40.63%
Cap/Sales(5y)27.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
EBIT growth 1Y-69.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y71.06%
EBIT Next 5YN/A
FCF growth 1Y89.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.64%
OCF growth 3Y-29.44%
OCF growth 5YN/A

AVID BIOSERVICES INC / CDMO FAQ

What is the ChartMill fundamental rating of AVID BIOSERVICES INC (CDMO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CDMO.


What is the valuation status of AVID BIOSERVICES INC (CDMO) stock?

ChartMill assigns a valuation rating of 1 / 10 to AVID BIOSERVICES INC (CDMO). This can be considered as Overvalued.


Can you provide the profitability details for AVID BIOSERVICES INC?

AVID BIOSERVICES INC (CDMO) has a profitability rating of 2 / 10.


What is the earnings growth outlook for AVID BIOSERVICES INC?

The Earnings per Share (EPS) of AVID BIOSERVICES INC (CDMO) is expected to grow by 86.15% in the next year.


Is the dividend of AVID BIOSERVICES INC sustainable?

The dividend rating of AVID BIOSERVICES INC (CDMO) is 0 / 10 and the dividend payout ratio is 0%.